A high-throughput screening strategy to overcome virus instability

Assay and Drug Development Technologies

Volumn 9, Issue 2, 2011, Pages 184-190

  Rasmussen, Lynn ^a   Maddox, Clinton ^a   Moore, Blake P ^a   Severson, William ^a   White, E Lucile ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOPATHOGENIC EFFECT; DRUG SCREENING; HEP 2 CELL; HIGH THROUGHPUT SCREENING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TISSUE CULTURE; VIRUS INFECTIVITY;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 79953785595     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0298     Document Type: Article

References (14)

1. Greenough A: Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med 2002;8:214-217.
2. Paramore LC: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004;22:275-284.
3. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379. (Pubitemid 32001022)
4. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG: A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-29.
5. Jordan WS Jr.: Growth characteristics of RSV. J Immunol 1962;88:581-590.
6. Sastre P, Oomens AGP, Wertz GW: The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein. Vaccine 2007;25:5025-5033. (Pubitemid 46880002)
7. Mason SW, et al.: Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 2004;32:4758-4767. (Pubitemid 39429680)
8. Noah JW, Severson W, Noah DL, Rasmussen L, White EL, Jonsson CB: A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res 2007;73:50-59. (Pubitemid 46080478)
9. Chung DH, Jonsson CB, Maddox C, McKellip SN, Moore BP, Heil M, White EL, Ananthan S, Li Q, Feng S, Rasmussen L: HTS-driven discovery of new chemotypes with West Nile virus inhibitory activity. Molecules 2010;15:1690-1704.
10. Severson WE, Shindo N, Sosa MI, Fletcher TM III, White EL, Ananthan S, Jonsson CB: Development and validation of a high throughput screen for inhibitors of SARS CoV and its application in screening a 100,000 compound library. J Biomol Screen 2007;12:33-40. (Pubitemid 46224917)
11. Li Q, Maddox C, Rasmussen L, Hobrath JV, White EL: Assay development and high-throughput antiviral drug screening against bluetongue virus. Antiviral Res 2009;83:267-273.
12. Severson WE, McDowell M, Ananthan S, Chung DH, Rasmussen L, Sosa MI, White EL, Noah J, Jonsson CB: High-throughput screening of a 100,000 compound library for inhibitors of Influenza A virus (H3N2). J Biomol Screen 2008;13:879-887.
13. Gonda MA, Braun MJ, Carter SG, Kost TA, Bess JW, Arthur LO, Van Der Maaten MJ: Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus. Nature 1987;330:388-391. (Pubitemid 18045469)
14. Zaman GJR, de Roos JADM, Blomenrohr J, van Koppen J, Oosterom J: Cryopreserved cells facilitate cell-based drug discovery. Drug Discov Today 2007;12:521-526. (Pubitemid 47039304)